/Investor DB

TVM Capital Life Science — 2024 Investments

2 investments dated 2024 · listed companies and verified rows first · show all

Csa Medical Increjuvenair.cominAug 2024

RejuvenAir, developed by CSA Medical, is a bronchoscopic cryosurgical device that sprays metered doses of liquid nitrogen to destroy damaged airway cells and treat the underlying cause of COPD with Chronic Bronchitis.

HealthtechMedical DevicesLutherville, US

Ellen Sheets(Executive Officer, Director)inIan J. Vawter(Executive Officer)Steven Schaefer(Executive Officer)inWilliam Floyd(Executive Officer, Director)inWendelin ManersinVincent Owens(Director)

Co-investorsAscension VenturesFirst AnalysisNew Markets Venture PartnersSV Health InvestorsBlue Heron CapitalTVM Capital

Vektor Medicalvektormedical.cominFeb 2024 · $16M

Vektor Medical develops patient-specific computational models of cardiac electrophysiology to support the diagnosis and treatment of heart arrhythmias.

AI & Machine LearningDigital HealthHealthtechMedical DevicesCarlsbad, US

Chris Villongco(Head of Technology / CTO)inRob Krummen(CEO (formerly President & COO))inKelly Perez(Head of Finance)inAlexander Michael Monko(Executive Officer, Director)

Co-investorsSolas BioVenturesTVM Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.